$ALAB

Gajendra Sanjay sold $39.5M of ALAB (indirect holdings)

Gajendra Sanjay (President and COO) sold 136,709 indirectly-held shares of Astera Labs, Inc. (ALAB) at $289.13 ($39.53M total) on 2026-05-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gajendra Sanjay
Published May 26, 2026, 8:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 8:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALAB
Neutral
medium confidence
Mentioned
$ALAB
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALABNeutralMed
01

Why it matters

The disclosure reports an open-market sale of 136,709 shares (~$39.53M) executed under a pre-arranged 10b5-1 plan, which generally lowers the probability that the sale signals deteriorating near-term outlook.

02

Market read

Traders may monitor for sentiment impact from large insider selling, but the 10b5-1 designation suggests planned activity rather than a new negative catalyst.

03

What to watch

Market may overreact to the dollar amount; traders should check whether there were concurrent insider buys/sales or other filings around the same period.

Relevance 8/10Timing: Immediate (filed 2026-05-26) but primarily informational; potential short-term headline-driven volatility.

Background

The article is an SEC Form 4 insider transaction disclosure for Astera Labs, Inc. (ALAB) by President and COO Gajendra Sanjay.

Company-level read

Ticker impact

$ALABNeutralMedium confidence
Context

Astera Labs COO sold $39.53M of ALAB shares in an open-market transaction under a pre-arranged 10b5-1 plan dated 2026-05-21.

Expected impact

Low likelihood of sustained price impact; any reaction may be brief and fade as the filing is understood as planned selling.

Evidence & confidence

Form 4 shows a large sale ($39.5M) but explicitly states it was executed under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal sector read-through; this is company-specific insider liquidity disclosure rather than operational/regulatory change.

None indicated; filing is US SEC EDGAR and not tied to regional demand/supply shifts.

None indicated; no international transaction or guidance change mentioned.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect routine diversification/compensation rather than negative fundamentals.

Key entities

  • Astera Labs, Inc.

    Company whose shares were sold by an officer/director under a 10b5-1 plan.

  • Gajendra Sanjay

    President and COO; sold 136,709 ALAB shares for ~$39.53M.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALABMed

ALAB Stock Holds Support As High Valuation Tests Traders

Astera Labs Inc. (ALAB) stock rose 6.54% due to strong AI infrastructure demand. The company reported $392.4M in quarterly revenue, $153.1M in net income, and $67.2M in free cash flow. ALAB trades at 127x earnings and 37x sales, with a strong balance sheet but high valuation concerns. Traders are watching key price levels around $262–$265 and $272–$275.

$ALABMed

ALAB Broadens Leo Portfolio: Can It Stay Ahead of MRVL & CRDO?

Astera Labs (ALAB) reported record Q2 2026 revenue growth, driven by AI connectivity products. The company expanded its Leo CXL memory controller portfolio, gaining hyperscaler traction. Q3 2026 revenue is expected between $540M and $560M. Competitors Marvell (MRVL) and Credo (CRDO) are also advancing in AI connectivity. ALAB shares rose 51.8% YTD, with a forward P/S of 16.16X.

$ALABMed

Why Is Astera Labs Stock Down Today?

Astera Labs (NASDAQ: ALAB) shares dropped 10.1% on Sept. 14, 2026, after AI leaders called for slower AI development, threatening demand for its data-center networking products. The decline was steeper than the S&P 500's 0.3% and Nasdaq's 0.1% drops.

$ALABMed

Astera Labs’ Scorpio X Is Already in Volume Production. Citi Showed How Fast the Customer List Is Growing

Astera Labs (ALAB) announced its Scorpio X product line is in volume production and expects revenue growth, with customer engagements increasing. The company guided Q3 revenue to $540M-$560M. Shares dropped after missing S&P 500 inclusion. Analysts set a mid-target price of ~$715, citing potential total return of ~146%. Risks include customer concentration and valuation multiple compression.

$ALABMed

ALAB Gains From Aries and Taurus Strength: Can It Beat MRVL & CRDO?

Astera Labs (ALAB) reports strong Q2 2026 revenue growth driven by demand for Aries and Taurus connectivity solutions, with PCIe 6 products accounting for over 50% of total revenue. The company expects Q3 2026 revenues of $540M-$560M, up 40% sequentially. ALAB competes with Marvell (MRVL) and Credo (CRDO) in the AI connectivity market. ALAB's stock has surged 73.7% YTD, with a forward P/S of 18.64x.